Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Free Cash Flow (2019 - 2026)

ADC Therapeutics has reported Free Cash Flow over the past 8 years, most recently at -$29.7 million for Q1 2026.

  • Quarterly results put Free Cash Flow at -$29.7 million for Q1 2026, up 47.45% from a year ago — trailing twelve months through Mar 2026 was -$114.6 million (up 16.16% YoY), and the annual figure for FY2025 was -$141.4 million, down 13.42%.
  • Free Cash Flow reached -$29.7 million in Q1 2026 per ADCT's latest filing, up from -$31.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $2195.0 in Q3 2022 and bottomed at -$138.2 million in Q4 2022.
  • Median Free Cash Flow over the past 5 years was -$29.4 million (2025), compared with a mean of -$32.5 million.
  • The largest annual shift saw Free Cash Flow surged 103.75% in 2022 before it plummeted 1790168.34% in 2023.
  • Over 5 years, Free Cash Flow stood at -$138.2 million in 2022, then surged by 79.16% to -$28.8 million in 2023, then increased by 21.27% to -$22.7 million in 2024, then plummeted by 38.38% to -$31.4 million in 2025, then grew by 5.24% to -$29.7 million in 2026.
  • Business Quant data shows Free Cash Flow for ADCT at -$29.7 million in Q1 2026, -$31.4 million in Q4 2025, and -$29.4 million in Q3 2025.